Greenville Leader

On Dec. 14, KIYATEC, Inc., announced its plans of expansion into Greenville County, whereby it will be investing $5 million and creating 91 new jobs, according to Upstate SC Alliance.

“Securing testing capacity to bring our testing to thousands, then tens of thousands of cancer patients is a business decision that positions us to win and increases our competitive advantage. As a Greenville-based life sciences company, KIYATEC benefits from all this area has to offer, including its highly educated labor force, excellent quality of life for our employees, competitive cost profile and business-friendly environment. We are proud to be a part of the growing business and scientific communities here in Greenville and appreciate the ongoing support from our community leaders in this exciting new phase of our company’s journey,” KIYATEC CEO Matt Gevaert told Upstate SC Alliance.

Founded in 2005, KIYATEC, a commercial stage cancer diagnostics company born from technology developed at Clemson University, is creating transformative solutions for cancer patients using functional precision oncology. KIYATEC recently launched its first commercial assay, 3D Predict Glioma, for use in glioblastoma (commonly known as GBM) and other brain cancer patient care.

The company established its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. It began clinical studies in 2015, developing proprietary “ex vivo” 3D cell culture technology platforms to accurately model and predict patient-specific responses to approved and investigational cancer drugs targeting a spectrum of solid tumors.

KIYATEC's downtown facility will be located at 2 N. Main Street in Greenville and will allow the company to expand its existing clinical testing operations and drug development services, which are colocated with the Cancer Institute at nearby Prisma Health’s Memorial Campus. This new facility will be the anchor tenant of the city of Greenville’s new Innovation District.